Objectives: To assess the performance of the commercially available Magmaris sirolimuseluting bioresorbable scaffold (BRS) with invasive imaging at different time points.
| INTRODUCTION
Bioresorbable scaffolds (BRS) provide short-term vessel scaffolding while avoiding long-term consequences of metallic drug-eluting stents (DES) . Recent studies demonstrated higher rates of clinical events with polymeric BRS as compared to contemporary metallic DES. 1 In order to improve BRS performance, alternative backbone materials such as magnesium are currently under investigation. First generations of absorbable magnesium scaffolds (AMS-1 and AMS-2; Biotronik, Berlin, Germany) failed to maintain vessel support due to rapid degradation process. 2 Later iterations of the device (DREAMS and DREAMS 2G;
Biotronik AG, Bülach, Switzerland) demonstrated safety and efficacy in the BIOSOLVE I and BIOSOLVE II trials. 3, 4 The Magmaris sirolimuseluting BRS (Biotronik AG) represents the latest generation and is currently being tested in the BIOSOLVE III and IV studies.
We present the findings of clinical and intravascular imaging at different time points following the commercial use of the Magmaris sirolimus-eluting BRS. 
| MATERIALS AND METHODS

| RESULTS
All patients presented with stable angina and noncomplex single-vessel coronary artery disease. Mean age was 57.2 years and 50% were male.
One scaffold per patient was implanted; mean BRS diameter and length were 3.08 ± 0.20 and 20.00 ± 4.47 mm, respectively. High-pressure predilatation and post-dilatation was implemented in all cases using noncompliant (NC) balloons. (see Tables S1 and S2). OCT post-procedure was performed in five cases. Procedural and device success was 100%.
Patients were discharged on dual antiplatelet therapy (DAPT) for at least 12 months along with high-intensity statin treatment.
Offline pre-percutaneous coronary intervention (pre-PCI) QCA revealed a lesion length of 16.50 ± 4.61 mm, percentage diameter stenosis (%DS) of 61.95 ± 5.30%, and a reference vessel diameter (RVD) of 2.75 ± 0.25. Pre-dilatation balloon diameter/RVD ratio was 1.10 ± 0.10. BRS diameter/RVD ratio was 1.13 ± 0.10, and post-dilatation balloon diameter/BRS diameter ratio was 1.14 ± 0.10. Residual %DS was 22.41 ± 8.13%. Acute recoil was 5.34 ± 3.99%. Offline postpercutaneous coronary intervention (post-PCI) OCT showed a minimal lumen area (MLA) of 5.64 ± 1.47 mm 2 and a minimal scaffold area (MSA) of 5.62 ± 1.60 mm 2 . Scaffold expansion (SE) according to reference vessel area (SE-RVA) was 91.04 ± 18.13% and scaffold expansion according to manufacturer's expected area (SE-MEA) was 73.84 ± 16.33%. Eccentricity index and symmetry index were 0.88 ± 0.01 and 0.32 ± 0.08, respectively. Incomplete strut apposition was 3.16 (p = .043) ( Figure 1 and Table 1 ). Percentage lumen area (%LA) stenosis was 56.64% with a binary restenosis rate of 83.3%.
In a per-scaffold subsegment analysis, a strong linear correlation between SA at baseline and %LA reduction at follow-up was found (r = −.87, p = .001). Furthermore, a similar correlation was present between SE at baseline and %LA reduction at follow-up according to both RVA and MEA (r = −.86, p = .001 and r = − .85, p = .002, respectively) (see Figure S2a The Magmaris BRS starts its degradation process as soon as 3 months and completes at 12 months. 6 Our results revealed a significant decrease in patent struts with a heterogeneous resorption pattern as soon as 4-5 months postimplantation; the latest was demonstrated by an important reduction of attenuation and backscattering indices; this is in line with a serial OCT imaging analysis performed in the BIOSOLVE II trial, showing a significant decrease in MLA of 28.3% at 6 months, and reduction of attenuation and backscattering values with fewer struts remnants visible. 3, 7 A rapid bioresorption rate might induce nonuniform vessel support and loss of radial strength, which has been corroborated with the first generation of Absorb BVS and magnesium BRS. 2, 8 The present report suggests that the most recent version of magnesium BRS also suffers from premature dismantling.
Whether the high LA reduction as found in our study could be attributed to a lower radial strength secondary to rapid bioresorption, an excessive neointimal formation, or both, is yet to be proven. Complete SA and neointimal volumes throughout the scaffolded segment could not be determined due to the difficulty in recognizing patent struts; however, when the SA was analyzable, a significant reduction of SA was found compared to the postimplantation result at the same location. These findings are in line with seven recently published case reports on severe lumen reduction and scaffold collapse after Magmaris BRS implantation. 9-15 Furthermore, acute recoil was only 5.3%, in line with current generation metallic DES and BVS. 16, 17 Preclinical data have suggested that increased local inflammation is responsible for the higher LLL obtained during the Magmaris degradation process, and a switch to a progressive positive vessel remodeling once the bioresorption is completed might be expected. 18 The latest warrants for serial invasive evaluation of the vessel response beyond 12 months. Nevertheless, vessel constrictive remodeling occurs between 1 and 6 months after PCI; therefore, assuring optimal radial support for at least 6 months after device implantation seems to be crucial. 19 Although careful lesion preparation and systematic high-pressure post-dilatation with NC balloons were routinely performed in all cases, a trend toward enhanced lumen loss in the distal scaffold edges was noticed. The latter appeared to be strongly linked to the postprocedural SA and lower SE at the most distal scaffold subsegments, compared to the middle and proximal subsegments. This discrepancy could be explained by the presence of smaller vessel diameter in the distal subsegments leading to scaffold oversizing, and potentially less aggressive post-dilatation due to the challenge in visualizing the tantalum markers. OCT assessment of magnesium BRS has shown an 
| Study limitations
This is a nonrandomized single-center study with small sample size. 
Patient and lesion selection was
